{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:23:05Z","timestamp":1794536585462,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50502-5","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:57:01Z","timestamp":1777359421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of potential CDK9 inhibitors through pharmacophore-based virtual screening, 3D-QSAR, molecular docking, MD simulation, and in vitro anticancer evaluation"],"prefix":"10.1038","volume":"16","author":[{"given":"Rajkumar","family":"Reddyrajula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umadevi","family":"Etikyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dinesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parayya Vibhutimath","family":"Sampat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreeganesh Subraya","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Muzaffar-Ur-Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Sekhar Kondapalli Venkata","family":"Gowri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayakumar","family":"Dalimba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijjulatha","family":"Manga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"50502_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer. 9, 153\u2013166 (2009).","journal-title":"Nat. Rev. Cancer."},{"key":"50502_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev.pharmtox.39.1.295","volume":"39","author":"DG Johnson","year":"1999","unstructured":"Johnson, D. G. & Walker, C. L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39, 295\u2013312 (1999).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"50502_CR3","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim, S. & Kaldis, P. Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development 140, 3079\u20133093 (2013).","journal-title":"Development"},{"key":"50502_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo, S., Damato, A., Alfano, L. & Giordano, A. CDK9 inhibitors in acute myeloid leukemia. J. Exp. Clin. Cancer Res. 37, 36 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"50502_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0378-1119(00)00278-X","volume":"254","author":"G Napolitano","year":"2000","unstructured":"Napolitano, G., Majello, B., Licciardo, P., Giordano, A. & Lania, L. Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II. Gene 254, 139\u2013145 (2000).","journal-title":"Gene"},{"key":"50502_CR6","doi-asserted-by":"publisher","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","volume":"59","author":"YA Sonawane","year":"2016","unstructured":"Sonawane, Y. A. et al. Cyclin dependent kinase 9 inhibitors for cancer therapy: Miniperspective. J. Med. Chem. 59, 8667\u20138684 (2016).","journal-title":"J. Med. Chem."},{"key":"50502_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/jcb.26293","volume":"119","author":"LC Franco","year":"2018","unstructured":"Franco, L. C., Morales, F., Boffo, S. & Giordano, A. CDK9: A key player in cancer and other diseases. J. Cell. Biochem. 119, 1273\u20131284 (2018).","journal-title":"J. Cell. Biochem."},{"key":"50502_CR8","doi-asserted-by":"publisher","first-page":"14647","DOI":"10.1021\/acs.jmedchem.1c01148","volume":"64","author":"X Han","year":"2021","unstructured":"Han, X. et al. Rational design and development of novel CDK9 inhibitors for the treatment of acute myeloid leukemia. J. Med. Chem. 64, 14647\u201314663 (2021).","journal-title":"J. Med. Chem."},{"key":"50502_CR9","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1021\/acs.jmedchem.1c01249","volume":"64","author":"B Barlaam","year":"2021","unstructured":"Barlaam, B. et al. Discovery of a series of 7-azaindoles as potent and highly selective CDK9 inhibitors for transient target engagement. J. Med. Chem. 64, 15189\u201315213 (2021).","journal-title":"J. Med. Chem."},{"key":"50502_CR10","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","volume":"63","author":"B Barlaam","year":"2020","unstructured":"Barlaam, B. et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J. Med. Chem. 63, 15564\u201315590 (2020).","journal-title":"J. Med. Chem."},{"key":"50502_CR11","doi-asserted-by":"publisher","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","volume":"63","author":"T Wu","year":"2020","unstructured":"Wu, T. et al. Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: An update. J. Med. Chem. 63, 13228\u201313257 (2020).","journal-title":"J. Med. Chem."},{"key":"50502_CR12","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1021\/acs.jmedchem.4c00312","volume":"67","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Recent discovery and development of inhibitors that target CDK9 and their therapeutic indications. J. Med. Chem. 67, 5185\u20135215 (2024).","journal-title":"J. Med. Chem."},{"key":"50502_CR13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/acs.jmedchem.4c02441","volume":"68","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Structure-guided discovery of novel N 4-(substituted thiazol-2-yl)-N 2-(4-substituted phenyl) pyrimidine-2, 4-diamines as potent CDK2 and CDK9 dual inhibitors with high oral bioavailability. J. Med. Chem. 68, 1693\u20131715 (2025).","journal-title":"J. Med. Chem."},{"key":"50502_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pr10122512","volume":"10","author":"ASM Saikat","year":"2022","unstructured":"Saikat, A. S. M. et al. Nature-derived compounds as potential bioactive leads against CDK9-induced cancer: Computational and network pharmacology approaches. Processes 10, 2512 (2022).","journal-title":"Processes"},{"key":"50502_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biom16010012","volume":"16","author":"L Piazza","year":"2025","unstructured":"Piazza, L. et al. Machine learning-based virtual screening for the identification of novel CDK-9 inhibitors. Biomolecules 16, 12 (2025).","journal-title":"Biomolecules"},{"key":"50502_CR16","volume":"42","author":"K Asamitsu","year":"2025","unstructured":"Asamitsu, K., Hirokawa, T. & Okamoto, T. Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico. Biochem. Biophys. Rep. 42, 101988 (2025).","journal-title":"Biochem. Biophys. Rep."},{"key":"50502_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00894-024-06067-z","volume":"30","author":"P Singh","year":"2024","unstructured":"Singh, P. et al. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations. J. Mol. Model. 30, 267 (2024).","journal-title":"J. Mol. Model."},{"key":"50502_CR18","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1021\/acsmedchemlett.4c00337","volume":"15","author":"Q Yang","year":"2024","unstructured":"Yang, Q. et al. Identification of potent CDK9 inhibitors with novel skeletons via virtual screening, biological evaluation, and molecular dynamics simulation. ACS Med. Chem. Lett. 15, 1654\u20131661 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"50502_CR19","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1039\/D3CP05582E","volume":"26","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Potent inhibitors targeting cyclin-dependent kinase 9 discovered via virtual high-throughput screening and absolute binding free energy calculations. Phys. Chem. Chem. Phys. 26, 5377\u20135386 (2024).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"50502_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1473398","volume":"12","author":"AA Alsfouk","year":"2024","unstructured":"Alsfouk, A. A., Faris, A., Cacciatore, I. & Alnajjar, R. Development of novel CDK9 and CYP3A4 inhibitors for cancer therapy through field and computational approaches. Front. Chem. 12, 1473398 (2024).","journal-title":"Front. Chem."},{"key":"50502_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118228","volume":"258","author":"M Wu","year":"2020","unstructured":"Wu, M. et al. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation. Life Sci. 258, 118228 (2020).","journal-title":"Life Sci."},{"key":"50502_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2023.108003","volume":"108","author":"I Habib","year":"2024","unstructured":"Habib, I. et al. Integrated computational approaches for designing potent pyrimidine-based CDK9 inhibitors: 3D-QSAR, docking, and molecular dynamics simulations. Comput. Biol. Chem. 108, 108003 (2024).","journal-title":"Comput. Biol. Chem."},{"key":"50502_CR23","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1021\/acs.jmedchem.9b02121","volume":"63","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Discovery and SARs of 5-Chloro-N 4-phenyl-N 2-(pyridin-2-yl) pyrimidine-2, 4-diamine derivatives as oral available and dual CDK 6 and 9 inhibitors with potent antitumor activity. J. Med. Chem. 63, 3327\u20133347 (2020).","journal-title":"J. Med. Chem."},{"key":"50502_CR24","doi-asserted-by":"publisher","first-page":"15340","DOI":"10.1021\/acs.jmedchem.3c01400","volume":"66","author":"T Wu","year":"2023","unstructured":"Wu, T. et al. Discovery of selective and potent macrocyclic CDK9 inhibitors for the treatment of Osimertinib-resistant non-small-cell lung cancer. J. Med. Chem. 66, 15340\u201315361 (2023).","journal-title":"J. Med. Chem."},{"key":"50502_CR25","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1021\/acs.jmedchem.3c02329","volume":"67","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y. et al. Identification of a novel selective CDK9 inhibitor for the treatment of CRC: Design, synthesis, and biological activity evaluation. J. Med. Chem. 67, 4739\u20134756 (2024).","journal-title":"J. Med. Chem."},{"key":"50502_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"50502_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.biori.2017.10.002","volume":"1","author":"D Rathee","year":"2017","unstructured":"Rathee, D., Lather, V. & Dureja, H. Pharmacophore modeling and 3D QSAR studies for prediction of matrix metalloproteinases inhibitory activity of hydroxamate derivatives. Biotechnol. Res. Innov. 1, 112\u2013122 (2017).","journal-title":"Biotechnol. Res. Innov."},{"key":"50502_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/10799893.2021.1999472","volume":"42","author":"V Kuchana","year":"2022","unstructured":"Kuchana, V., Kashetti, V., Peddi, S. K. R., Sivan, S. & Manga, V. Integrated computational approach for in silico design of new purinyl pyridine derivatives as B-Raf kinase inhibitors. J. Recept. Signal Transduct. 42, 439\u2013453 (2022).","journal-title":"J. Recept. Signal Transduct."},{"key":"50502_CR29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s11030-024-10887-9","volume":"29","author":"U Etikyala","year":"2025","unstructured":"Etikyala, U. et al. An in silico approach to identify novel and potential Akt1 (protein kinase B-alpha) inhibitors as anticancer drugs. Mol. Divers. 29, 1009\u20131032 (2025).","journal-title":"Mol. Divers."},{"key":"50502_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.138569","volume":"1312","author":"U Etikyala","year":"2024","unstructured":"Etikyala, U. et al. Design, synthesis and molecular docking of 5-fluoro indole derivatives as inhibitors of PI3K\/Akt signalling pathway in cervical cancer. J. Mol. Struct. 1312, 138569 (2024).","journal-title":"J. Mol. Struct."},{"key":"50502_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117562","volume":"98","author":"R Reddyrajula","year":"2024","unstructured":"Reddyrajula, R., Etikyala, U., Manga, V. & Dalimba, U. Discovery of 1, 2, 3-triazole incorporated indole-piperazines as potent antitubercular agents: Design, synthesis, in vitro biological evaluation, molecular docking and ADME studies. Bioorg. Med. Chem. 98, 117562 (2024).","journal-title":"Bioorg. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50502-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:01:21Z","timestamp":1782716481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50502-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50502-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9086560\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19651"}}